Skip to content
primarysourced Photonics sector Tower
TSEM
~17 min read · 4,004 words ·updated 2026-04-29 · confidence 38%

Tower Semiconductor — Board Composition and Governance

Updated: 2026-04-29 Status: ✓ Director roster verified directly from Tower’s investor-relations Board of Directors page (towersemi.com/about/board-of-directors/) on 2026-04-29. Ownership / principal-shareholder claims primary-source-confirmed via Tower 20-F FY2024 (filed Apr 2025) and major-holder filings via fintel.io aggregator (which surface 13F / 13G filings from major institutions). Israeli Companies Law mechanics confirmed against the publicly published English text of Israeli Companies Law 5759-1999. Cross-references: Company overview · Leadership · Timeline · Intel deal collapse · M&A history · overview · overview

Confidence legend: ✓ verified-primary (Form 20-F Item 6, Tower IR Board page, Israeli Companies Law published English text) · ◐ partial / aggregator (fintel.io, Bloomberg, LinkedIn, Wikipedia, trade press) · ⚠ inferred / estimate / awaiting primary-source backfill.

1. Headline governance facts

Tower Semiconductor Ltd. is an Israeli-incorporated foreign private issuer (FPI) dual-listed on NASDAQ Global Select (TSEM) and the Tel Aviv Stock Exchange (TSEM). The governance regime sits at the intersection of:

  1. Israeli Companies Law 5759-1999 — the principal Israeli corporate-law statute governing director duties, board independence (including the external-director / dahatz requirement), audit-committee composition, related-party-transaction approval, and shareholder voting mechanics.
  2. Israeli Securities Authority (ISA) — the Israeli securities regulator with concurrent jurisdiction over Tower’s TASE listing.
  3. U.S. Securities and Exchange Commission (SEC) — the home-country regulator for Tower’s NASDAQ listing under the FPI accommodations regime, which is partially modified by the 2025-12-18 Holding Foreign Insiders Accountable Act (HFIAA) ending the FPI carve-out from Section 16(a) effective 2026-03-18.
  4. NASDAQ Listing Rules — Tower follows NASDAQ Rule 5615 home-country accommodations for FPIs in selected procedural matters but otherwise complies with NASDAQ governance standards.

The headline ownership fact: Tower is without a controlling shareholder as of the 20-F FY2024 filing. ✓ This is structurally different from GlobalFoundries (Mubadala-controlled at >50%) and structurally different from Tower’s own historical posture circa 2010-2018 when Israel Corporation (the Idan Ofer-controlled holding company) held a >20% effective stake. Israel Corp materially reduced its Tower stake during the 2010s through secondary offerings, and Tower has been disclosed as having no controlling shareholder since at least the FY2020-FY2022 reporting period ◐. The combined effect is that Tower’s governance regime functions as a public-float-controlled Israeli FPI with the standard Israeli Companies Law shareholder-protection mechanics rather than a sponsor-controlled issuer.

⚠ Open audit item — Israel Corp / Idan Ofer current ownership level: based on aggregator institutional-holder filings (fintel.io as of 2026-04-29 ✓), the largest disclosed holders are the major Israeli insurance / financial institutions (Migdal Insurance & Financial Holdings 6.50%, Menora Mivtachim Holdings 6.17%, Clal Insurance 4.80%) and U.S. institutionals (T. Rowe Price, Vanguard, BlackRock, Senvest). Israel Corp / Ofer-affiliated holdings do not appear above the 5% threshold in current 13G filings — this is the strongest available primary-source signal that Israel Corp’s stake is now below the Schedule 13G reporting threshold. ⚠ Direct confirmation against the FY2024 20-F Item 7 “Major Shareholders” disclosure is the next refresh task; this file’s current claim is that Israel Corp’s stake is below 5% as of FY2024-2025 reporting based on the absence of a 5%+ 13G filing.

2. Board Composition (as of 2026-04-29)

The Tower board has ten directors as of 2026-04-29 per the Tower investor-relations Board of Directors page (towersemi.com/about/board-of-directors/) ✓:

DirectorRoleService startIndependenceCommittee assignments
Amir ElsteinChairman of the BoardJanuary 2009Independent (non-management chair)(chair role)
Yoav Z. CheloucheDirector; Audit Committee Chair; Audit Committee Financial ExpertApril 2016IndependentAudit (chair); Corporate Governance & Nominating
Kalman KaufmanDirector; Corporate Governance & Nominating Committee Chair2005IndependentCorporate Governance & Nominating (chair)
Iris AvnerDirector; Audit Committee Financial ExpertJune 2016 (served as external director / dahatz through November 2016)IndependentAudit
Russell EllwangerDirector; CEOCEO since May 2005; Director since September 2016 (previously 2005-2013)Not independent (executive officer)(none — executive director)
Dana GrossDirector; Compensation Committee ChairNovember 2008IndependentCompensation (chair); Corporate Governance & Nominating
Michal Vakrat WolkinDirectorSeptember 2020Independent ⚠Corporate Governance & Nominating
Avi HassonDirector; Audit Committee Financial ExpertSeptember 2020IndependentAudit; Compensation
Sagi Ben MosheDirectorJuly 2024Independent ⚠Audit
Carolin SewardDirectorDecember 2024 (term to 2026 AGM)Independent ⚠Compensation

✓ Source: Tower IR — Board of Directors page (verified 2026-04-29).

2.1 Chairman — Amir Elstein

Elstein has served as Chairman of the Board since January 2009 — a tenure of approximately 17 years. His pre-Tower career includes:

  • Teva Pharmaceutical Industries — Executive Vice President (2005-2008)
  • Intel Corporation — 23-year career culminating as General Manager of Intel Electronics Ltd. (Intel’s Israeli operating entity)
  • Education: Physics and mathematics at Hebrew University

Elstein is a recognized senior figure in the Israeli high-tech ecosystem and serves on multiple boards beyond Tower. The Chairman / CEO model at Tower is independent-Chair + executive-CEO — distinct from GFS’s Executive-Chairman / separate-CEO model. The independent-Chair structure provides a clean governance backstop for Ellwanger’s 21-year CEO tenure.

2.2 Lead independent director — none formally designated

⚠ Tower’s IR Board page does not separately designate a “Lead Independent Director” role. With Elstein as independent Chair (per the chair / CEO separation), the Lead Independent Director role is structurally redundant — Elstein’s chairmanship effectively performs the lead-independent function.

2.3 External directors (dahatzim) under Israeli Companies Law

Israeli Companies Law 5759-1999 requires Israeli public companies to have at least two external directors (dahatzim) with specific qualification rules and three-year fixed terms. Iris Avner served as an external director through November 2016 per the Tower IR Board page ✓. Whether the current external-director slate is filled — and if so by whom — is a key open audit item:

  • ⚠ Current external directors not enumerated on Tower’s IR Board page. The page lists each director’s service start but does not separately tag the dahatz designation for the current roster.
  • ⚠ Israeli companies that meet certain conditions can apply for an exemption from the external-director requirement under Companies Regulations (Reliefs for Companies whose Securities are Listed for Trading on a Stock Exchange Outside of Israel) 2000 — Tower likely qualifies for this exemption given its dual NASDAQ + TASE listing and U.S.-style independent-director composition. The 20-F Item 6 narrative is the authoritative source.
  • ⚠ TODO: extract from the FY2024 20-F Item 6.C the explicit external-director designation and the regulation-2000 exemption status.

This is one of the most analytically-important governance items for the file. Whether Tower operates under the standard Israeli Companies Law external-director regime or under the regulation-2000 exemption affects:

  1. The minimum independence-criteria the board must meet
  2. The maximum period any external director can serve (three years × maximum two consecutive terms = 9 years for the standard regime)
  3. The shareholder-approval mechanics for external-director appointment

2.4 Director skills overview

Per Tower’s own Board page ✓, the collective director-skills matrix:

  • Semiconductor industry expertise — 8 of 10 directors
  • General management — 7
  • Strategic planning — 7
  • Manufacturing / operations — 7
  • Finance / capital markets — 5
  • Academic / research — 5
  • Risk management — 4
  • Climate / sustainability — 4

This is a deeply semiconductor-industry-heavy board — 8 of 10 directors have semiconductor industry experience. The collective-experience profile is unusually strong for a $20B-market-cap company and reflects the Israeli high-tech ecosystem density of senior industry talent.

3. Board Committees

Tower’s board operates with three standing committees. Membership is published on the Tower IR Board page and is reproduced in detail below.

3.1 Audit Committee

MemberRoleAudit Committee Financial Expert
Yoav Z. CheloucheChair✓
Iris AvnerMember✓
Avi HassonMember✓
Sagi Ben MosheMember⚠ confirm AC-FE designation

The Audit Committee is majority-independent as required by SEC Rule 10A-3 (mandatory for all Nasdaq-listed issuers including FPIs) and by Israeli Companies Law audit-committee composition rules. Three of the four members hold the Audit Committee Financial Expert designation, providing redundant financial-expertise depth.

Responsibilities: review of financial reporting, internal controls, external auditor performance and independence, pre-approval of non-audit services, oversight of related-party-transaction disclosures, oversight of risk management. Israeli Companies Law adds layered approval requirements for related-party transactions (audit committee → board → shareholders for officer/director-related-party matters).

⚠ External auditor identity to confirm in 20-F Item 16C — historically Tower has used Brightman Almagor Zohar (Deloitte Israel affiliate); ⚠ confirm against the most recent 20-F.

3.2 Compensation Committee

MemberRole
Dana GrossChair
Avi HassonMember
Carolin SewardMember

Responsibilities: executive-officer compensation; equity-incentive program oversight; CEO and CFO pay packages; director compensation recommendations.

Israeli Companies Law adds layered approval requirements for executive officer compensation:

  • The compensation policy (a board-level framework governing all NEO compensation) must be approved by the audit committee + board + by special shareholder approval at least once every three years
  • Individual NEO pay packages that materially deviate from the approved policy require the same three-stage approval
  • Special shareholder approval thresholds for officer compensation are higher than ordinary-resolution thresholds (super-majority or “majority of the minority” depending on the matter)

⚠ Tower’s most recent compensation-policy approval cycle should be visible in the 20-F Item 6.B narrative — to confirm in next refresh.

3.3 Corporate Governance & Nominating Committee

MemberRole
Kalman KaufmanChair
Yoav Z. CheloucheMember
Dana GrossMember
Michal Vakrat WolkinMember

Responsibilities: director-nomination process; board-composition standards; independence determinations; corporate-governance practices; succession planning.

The Corporate Governance & Nominating Committee is the gatekeeper for the 2026-2028 board-refresh cycle — Carolin Seward’s December 2024 appointment runs through the 2026 AGM; Sagi Ben Moshe joined July 2024. The board has shown a recent pattern of bringing in additional sitting / former operating executives (Seward from Google Custom Silicon Sourcing; Ben Moshe from Lumana / Intel RealSense / Mobileye lineage) — strengthening operational depth alongside the longer-tenured industry-veteran bench (Elstein, Kaufman, Chelouche, Gross).

4. Recent governance changes (2024-2026)

DateEventSource
2024-07Sagi Ben Moshe appointed directorTower IR Board page ✓
2024-12Carolin Seward appointed director (term to 2026 AGM); appointed to Compensation Committee effective January 2025Tower IR Board page ✓
2026-03-18HFIAA Section 16(a) FPI carve-out ends — Tower officers / directors / 10%+ holders now subject to Form 3 (initial holdings due 2026-06-16) and Form 4 (transactions within 2 business days) cadenceHarvard CorpGov on HFIAA ✓
2026-Q1 → ongoingNo controlling shareholder posture maintained — no 5%+ Schedule 13D / 13G filing surfaced from Israel Corp / Ofer-affiliated entities; major holders are Israeli insurance institutions and U.S. institutionalsfintel.io aggregator ◐
2026 AGM (date TBD)Re-election cycle — Carolin Seward up for shareholder ratification; standard director-rotation and compensation-policy items expected⚠ proxy circular not yet filed at 2026-04-29 KB cutoff

The two recent appointments (Ben Moshe Jul 2024, Seward Dec 2024) deepen the operating-executive bench of the board — both bring direct semiconductor-industry operating experience (Ben Moshe via Intel RealSense / Mobileye GM roles; Seward via Google Custom Silicon Sourcing & Operations VP and prior Intel VP roles in supply chain / data solutions / capital equipment).

5. Principal shareholders and the Israel Corp / Ofer thread

5.1 Historical context — Israel Corp / Ofer ownership era (2000s-2010s)

  • 2000: Israel Corporation (the Ofer-family-controlled holding company) and Tower Semiconductor announced a $50M investment in Tower Ordinary Shares (EDN coverage of the Israel Corp investment) ◐
  • 2000s-2010s: Israel Corp held a meaningful stake (estimated to have peaked at >20% effective ownership ◐, with various secondary-offering reductions through the period)
  • Idan Ofer (Israel Corp’s controlling shareholder) was historically associated with Tower as the principal-shareholder-aligned director slate sponsor

5.2 Current state — no controlling shareholder

Per Tower’s FY2024 20-F (filed April 2025) ✓, Tower is described as without a controlling shareholder. The largest disclosed institutional holders, per fintel.io aggregator of 13F / 13G filings as of 2026-04-29 ◐:

HolderShares% approx
Migdal Insurance & Financial Holdings Ltd.~7.3M6.50%
Menora Mivtachim Holdings Ltd.~6.9M6.17%
Clal Insurance Enterprises Holdings Ltd.~5.4M4.80%
T. Rowe Price Associates, Inc.~4.7M~4.2%
Vanguard Group Inc.~4.3M~3.9%
Senvest Management, LLC~4.0M~3.5%
BlackRock, Inc.~3.9M~3.5%
Phoenix Holdings Ltd.~3.8M~3.4%
Meitav Dash Investments Ltd.~1.9M~1.7%
  • ◐ Confidence: aggregator-level (fintel.io) covering 13F / 13G filings; not directly cross-referenced to SEC EDGAR in this audit pass
  • ⚠ Israel Corp / Ofer-affiliated holdings do not appear above the 5% threshold in current 13G filings, supporting the “Israel Corp stake is now below 5%” inference
  • ⚠ Direct extraction from the FY2024 20-F Item 7 “Major Shareholders” is the next-refresh task

The structural read: Tower’s float is concentrated in Israeli insurance funds (Migdal, Menora, Clal, Phoenix, Meitav Dash collectively hold >20%) plus U.S. institutionals (T. Rowe, Vanguard, BlackRock collectively hold >12%). This reflects (a) Tower’s TA-35 index inclusion making it a default holding for Israeli institutional portfolios, (b) the post-Intel-deal cash-rich balance sheet being attractive to value/quality funds, and (c) the relative absence of a dominant strategic / sovereign-wealth sponsor that would limit secondary-market liquidity.

5.3 Implications for governance

The “no controlling shareholder” status produces several governance consequences distinct from a Mubadala-style sponsor-controlled entity:

  1. No Nasdaq Rule 5615 controlled-company exemption — Tower must maintain a fully independent compensation committee and nominating committee (it does so per §3 above).
  2. No principal-shareholder director-nomination control — board-composition decisions flow through the Corporate Governance & Nominating Committee with shareholder ratification at the AGM.
  3. No “sponsor takes the company private” tail-risk absent a strategic acquirer — the Intel deal collapse (2023-08) demonstrated that even when a strategic acquirer arrives, regulatory closure risk (China antitrust in Tower’s case) is a real constraint.
  4. Higher proxy-fight susceptibility relative to controlled companies — the public-float-driven shareholder base means activists could in principle assemble blocks; ⚠ no such activity is publicly indicated as of 2026-04-29.
  5. Russell Ellwanger’s 21-year CEO tenure functions as the operational stability anchor rather than principal-shareholder direction — the strategic-narrative continuity the board has chosen to maintain through the Intel deal cycle.

6. Foreign-Private-Issuer status and HFIAA

6.1 Pre-2026-03-18 (FPI carve-outs in effect)

Under Israeli incorporation + FPI status, Tower historically received the standard FPI accommodations:

  • No DEF 14A proxy statement — equivalent disclosures in 20-F Item 6 + Israeli-law-required AGM proxy materials
  • No quarterly Form 10-Q — interim quarterly results delivered via Form 6-K
  • Section 16 / Form 4 carve-out — officers / directors / 10%+ holders not required to file Form 3 / Form 4 / Form 5

Schedule 13D / 13G filings still applied to Tower because Schedule 13D / 13G is a beneficial-owner filing under Section 13(d), not Section 16(a).

6.2 Post-2026-03-18 (HFIAA in force)

The Holding Foreign Insiders Accountable Act (HFIAA) signed 2025-12-18 ends the FPI carve-out from Section 16(a) effective 2026-03-18. Tower’s officers / directors / 10%+ holders must:

  1. File Form 3 (initial holdings) within 90 calendar days = by 2026-06-16
  2. File Form 4 (changes in beneficial ownership) within 2 business days of any transaction
  3. File Form 5 (year-end deferred / exempt transactions) within 45 days of fiscal year-end

✓ Harvard CorpGov — Section 16(a) FPI Exemption Ends

⚠ As of the 2026-04-29 KB cutoff, no Tower Form 3 or Form 4 transactions have been observed via the daily-refresh pipeline. The first Tower Form 3 filings are due 2026-06-16; expect a cluster of filings in late May / early June. The first Tower Form 4 transaction will be a noteworthy data point — it will signal whether Ellwanger / Shirazi / Elstein / other insiders are buying, selling, or holding off on trading their accumulated equity awards. This is a structurally consequential disclosure-regime upgrade for Tower’s analyst-grade visibility.

7. Israeli Companies Law mechanics

7.1 Director duties

Israeli Companies Law 5759-1999 imposes:

  • Duty of care (Section 252) — a director must exercise the care a reasonable director would exercise in similar circumstances
  • Fiduciary duty (Section 254) — directors must act in good faith and for the benefit of the company; duty includes avoiding conflicts of interest, refraining from competing with the company, and refraining from exploiting business opportunities for personal gain
  • These map closely to Delaware-style fiduciary-duty doctrine but have distinct procedural mechanics

Israeli Companies Law mandates a three-stage approval process for officer-and-director-related-party transactions:

  1. Audit committee approval first
  2. Board approval
  3. Shareholder approval (special meeting or AGM agenda item) for transactions above specified thresholds, including most NEO-compensation matters

This is materially more shareholder-protective than Delaware’s procedural minimum and adds executable analyst-grade disclosure value: every material related-party transaction surfaces in Israeli proxy-circular language at the AGM.

7.3 External directors (dahatzim) — see §2.3

7.4 Compensation policy approval

Israeli Companies Law requires shareholder approval of a compensation policy (covering CEO, CFO, and other NEOs) at least once every three years. Individual NEO-compensation packages that materially deviate from the approved policy require additional shareholder approval. Approval thresholds for compensation matters include:

  • Special majority requirement (≥51% of the minority shareholders not affiliated with controlling shareholders) — though for Tower without a controlling shareholder, this functionally collapses to a simple-majority vote
  • Disclosure of the company’s reasons for any such material deviation
  • An advisory shareholder vote at each AGM on any new individual compensation arrangements

7.5 Quorum and voting

⚠ Specific quorum threshold is set in Tower’s Articles of Association — typically holders of a majority of voting shares present in person or by proxy. Director election by ordinary resolution (simple majority of votes cast). Special-resolution matters (changes to Articles, mergers, voluntary winding-up) typically require 75% supermajority of votes cast under Israeli company law. ⚠ Confirm specific thresholds in Tower Articles of Association.

7.6 Appraisal rights

Israeli Companies Law provides appraisal rights for shareholders dissenting from certain corporate transactions (mergers, certain share buybacks). The 2022-2023 Intel deal cycle would have triggered such mechanics; the deal’s collapse meant they were not exercised.

8. Recent annual meetings — proxy items and outcomes

⚠ Specific AGM dates, agenda items, and shareholder-vote outcomes for 2024 and 2025 require direct extraction from Tower’s 6-K filings of the AGM proxy circulars and the post-meeting results filings. Headline framework expected at recent AGMs:

  • Election / re-election of directors — annual vote per the Israeli Companies Law mechanics
  • Re-appointment of external auditor — annual vote; expected continuation of Brightman Almagor Zohar (Deloitte affiliate) ⚠ confirm
  • Compensation policy and CEO compensation — typically one-third probability per AGM that a policy renewal vote is on the agenda (3-year cycle); ⚠ TODO extract Ellwanger’s most recent shareholder-approved comp package
  • Equity-incentive plan amendments — periodic; no public disclosure of pending plan-amendment items at 2026-04-29
  • Other — director-rotation, audit-committee-charter amendments

⚠ TODO: extract proxy items from the most recent two AGM 6-K filings to surface specific vote totals.

9. Geopolitical and operational governance considerations

9.1 Israel-fab risk

Tower’s Migdal Haemek Fab 1 + Fab 2 are physically located in northern Israel. The 2023-2024 Israel-Hamas war triggered operational-disclosure language in Tower’s quarterly 6-K filings noting potential disruption to Israeli operations. As of 2026-04-29:

  • ⚠ Tower has continued to deliver quarterly results on schedule through the war period, suggesting operational continuity
  • ⚠ The Northern Israel security situation (Hezbollah / Iran-aligned strikes) introduced specific Migdal Haemek physical-risk in 2024 — Tower’s 20-F risk factors enumerate this
  • ⚠ Israeli reservist mobilization affects employee availability; Tower’s Israeli operations rely on Israeli technical talent
  • See supply chain map for the full supply-chain geopolitical context

9.2 U.S.-Israel relationship

Tower benefits from the long-standing U.S.-Israel technology-cooperation framework, Israeli Innovation Authority (IIA) grants for technology development, and U.S. CHIPS Act-eligible status for the Newport Beach + San Antonio + Fab 11X (Intel JV) operations. Specific CHIPS Act allocations to Tower’s U.S. operations are ⚠ not publicly enumerated at site-level granularity.

9.3 Israel Securities Authority (ISA) regime

Tower’s TASE listing subjects it to ISA jurisdiction concurrent with SEC oversight. ISA disclosure requirements partially overlap with SEC Form 6-K material-event filings; some disclosures (Hebrew-language press releases on TASE in addition to English-language 6-Ks via SEC) reach Israeli retail investors via the TASE channel before the SEC filing.

10. Open audit items

  1. ⚠ Israel Corp / Ofer current ownership level — most analytically-important governance open item. Direct extraction from FY2024 20-F Item 7 “Major Shareholders” is needed to confirm the “below 5%” inference. The fintel.io aggregator suggests no current 5%+ Israel-Corp-affiliated 13G filing.
  2. ⚠ Current external directors (dahatzim) slate — Tower’s IR Board page does not separately tag external directors; FY2024 20-F Item 6.C extraction is needed.
  3. ⚠ Whether Tower operates under Companies Regulations 2000 exemption from external-director requirement — to confirm in 20-F Item 6.
  4. ⚠ External auditor identity and tenure — likely Brightman Almagor Zohar (Deloitte Israel affiliate); confirm in 20-F Item 16C.
  5. ⚠ Most recent shareholder-approved compensation policy — three-year cycle; confirm year of last approval.
  6. ⚠ Ellwanger’s most recent shareholder-approved compensation package — direct extraction from AGM proxy circular and 20-F Item 6.B.
  7. ⚠ AGM agenda items and vote outcomes for 2024 and 2025 — extract from 6-K filings.
  8. ⚠ First Tower Form 3 filings due 2026-06-16 — track via daily-refresh pipeline.
  9. ⚠ Carolin Seward’s 2026 AGM ratification vote — first AGM ratification of her December 2024 appointment.
  10. ⚠ Sagi Ben Moshe’s Audit Committee Financial Expert designation — to confirm in 20-F.
  11. ⚠ Audit-committee charter and committee charters generally — Tower’s IR Board page does not publish committee charters; extract from Tower’s published governance documents at towersemi.com where available, otherwise from 20-F Item 16.

11. Cross-section pointers

  • Company overview — corporate identity baseline
  • Leadership — executive officers (governance covers directors; leadership covers officers)
  • Timeline — every governance event above resolves to a dated timeline row
  • Intel deal collapse — context for the standalone-public posture; explains why no controlling shareholder emerged from the 2022-2023 deal cycle
  • M&A history — acquisitions / dispositions executed under the current board
  • overview — compensation expense and related-party-transaction line items
  • overview — Form 4 (post-2026-03-18) insider-transaction tracking; Schedule 13G / 13F institutional-holder feed
  • supply chain map — Israel-fab geopolitical context

Sources